Smartleaf Asset Management’s Immunic IMUX Stock Holding History

Smartleaf Asset Management’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2	Closed	-$22	–	3488
2026 Q1	$22	Hold	2	–	–	﹤0.01%	3467
2025 Q4	$11	Buy	+2	New	+$15	﹤0.01%	3475

Other funds holding IMUX

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Smartleaf Asset Management's IMUX Position: Q2 2026 in Review

Smartleaf Asset Management sold out of Immunic (IMUX) in Q2 2026, closing a stake of 2 shares — an estimated $22 sold.

Smartleaf Asset Management first reported a position in IMUX in Q4 2025 and held it in 2 quarters. The position peaked at $22 in Q1 2026. 55 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

Smartleaf Asset Management reported no remaining Immunic position as of Q2 2026 after selling out during the quarter.
Smartleaf Asset Management sold 2 Immunic shares in Q2 2026, an estimated $22.
Smartleaf Asset Management first reported a position in Immunic in Q4 2025 and held it in 2 quarters.
Smartleaf Asset Management's Immunic position peaked at $22 in Q1 2026.
55 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.